BioCardia Statistics
Total Valuation
BioCardia has a market cap or net worth of $10.69 million. The enterprise value is $6.87 million.
| Market Cap | 10.69M |
| Enterprise Value | 6.87M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioCardia has 11.37 million shares outstanding. The number of shares has increased by 132.95% in one year.
| Current Share Class | 11.37M |
| Shares Outstanding | 11.37M |
| Shares Change (YoY) | +132.95% |
| Shares Change (QoQ) | +11.85% |
| Owned by Insiders (%) | 22.11% |
| Owned by Institutions (%) | 18.76% |
| Float | 8.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.22 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.09 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,803.19% and return on invested capital (ROIC) is -498.79%.
| Return on Equity (ROE) | -1,803.19% |
| Return on Assets (ROA) | -134.97% |
| Return on Invested Capital (ROIC) | -498.79% |
| Return on Capital Employed (ROCE) | -273.70% |
| Weighted Average Cost of Capital (WACC) | 6.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$349,476 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.04% in the last 52 weeks. The beta is 0.49, so BioCardia's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -51.04% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 52.25 |
| Average Volume (20 Days) | 243,097 |
Short Selling Information
The latest short interest is 1.11 million, so 9.73% of the outstanding shares have been sold short.
| Short Interest | 1.11M |
| Short Previous Month | 1.34M |
| Short % of Shares Out | 9.73% |
| Short % of Float | 13.01% |
| Short Ratio (days to cover) | 3.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | -4.96M |
| Operating Income | -7.39M |
| Pretax Income | -7.34M |
| Net Income | -7.34M |
| EBITDA | -7.38M |
| EBIT | -7.39M |
| Earnings Per Share (EPS) | -$0.74 |
Balance Sheet
The company has $4.12 million in cash and $293,000 in debt, with a net cash position of $3.82 million or $0.34 per share.
| Cash & Cash Equivalents | 4.12M |
| Total Debt | 293,000 |
| Net Cash | 3.82M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 2.70M |
| Book Value Per Share | 0.18 |
| Working Capital | 2.24M |
Cash Flow
In the last 12 months, operating cash flow was -$7.56 million and capital expenditures -$9,000, giving a free cash flow of -$7.57 million.
| Operating Cash Flow | -7.56M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 13,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.57M |
| FCF Per Share | -$0.67 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioCardia does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -132.95% |
| Shareholder Yield | -132.95% |
| Earnings Yield | -68.64% |
| FCF Yield | -70.82% |
Analyst Forecast
The average price target for BioCardia is $15.50, which is 1,548.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 1,548.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | May 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |